(077) Testosterone Therapy in Men on Active Surveillance for Prostate Cancer

Abstract Introduction The role of testosterone therapy (TTH) in men with prostate cancer (PC) is debated, especially on active surveillance (AS). Objective This study aimed to review our data TTH this population. Methods population consisted (i) PC (ii) two total T (TT) levels <300 ng/dL (iii) associated symptoms performed using LCMS (v) conducted an early morning fashion who (vi) pursued (TTH). included exogenous (transdermal, intramuscular) and clomiphene citrate (CC) the setting low/low-normal LH levels. lab work including PSA levels, were checked within 4 weeks initiation, every three months first year six after that. Target TT level was middle tertile normal reference range at institution. We report group. Results 82 patients are included. Mean age = 64 ± 9 years. Median pre-TTH 4.6 [3.4, 6.7] ng/mL. baseline 305 145 ng/dL. 19% these had a <200 Gleason score (GS) 6 90% 3+3, 9% 3+4 1% 4+3. duration AS before 14 [1, 43] months. 45% received transdermal T, intramuscular 36% CC. Post-TTH 553 268 ng/dL, 4.9 [3.2, 9.2] last follow-up 39] change per patient 0.3 [-0.9, 2.6] ng/mL, representing median (-24, 70) % (p= 0.045). 42% decrease PSA, 58% increase. In 88% experienced rise rose ≥10%. 50% below above 4. 28% increase ≥1 ng/mL year. 18% men, stopped definitive treatment instituted. ≤1 another opted for treatment. most common reason anxiety. Conclusions treated TTH, minimal changes seen, equal numbers experiencing drop PSA. About fifth ceased proceeded their PC. Disclosure No